iGan Partners leads $10M round in Adenocyte to scale pancreatic cancer early-detection platform
What's the deal? Toronto-based venture firm iGan PartnersDealroom has a profile for this one. Try Dealroom → has led the first close of a $10M financing round in Adenocyte, an Israeli medtech company developing technology for the very early detection of pancreatic cancer. The final close is expected in June.
Adenocyte's LINFU platform — a 30-minute outpatient procedure — combines microbubble injection with low-intensity ultrasound to safely release pancreatic cells for analysis. The technology is FDA-cleared and already reimbursed by Medicare and many commercial insurers under existing billing codes.
The proceeds will fund clinical and commercial expansion, plus further development of the LINFU platform for sampling the pancreas, breast, and prostate.
Why now? Adenocyte has hit several milestones that make it investable. It has completed over 150 patient procedures at US endoscopy centres and presented results from its first 90 high-risk screenings at the US and Canadian Academy of Pathology annual meeting. Those results showed 100% specimen adequacy and detected four cases of unsuspected neoplasia — including one early-stage adenocarcinoma — that were invisible to other modalities like MRI.
The company also struck a collaboration with Quest DiagnosticsDealroom has a profile for this one. Try Dealroom → to process its cytology samples nationally. More leading pancreatic centres are preparing to adopt the platform in coming quarters.
"Pancreatic cancer is one of the deadliest cancers specifically because it is detected too late," said Sam Ifergan, founder and managing partner of iGan Partners. "Adenocyte's LINFU platform offers a reimbursable, scalable way to find this disease earlier, when treatment can be curative."
What could go wrong? Pancreatic cancer screening is notoriously difficult, and early-detection technologies have a long history of failing to scale commercially. Adenocyte's clinical dataset — 150 procedures and 90 screened patients — is still small. Broader adoption will require larger studies and buy-in from gastroenterologists who may be cautious about new workflows.
The company is also based in Haifa and Jerusalem, with clinical operations in the US, adding cross-border complexity to its expansion plans.
The signal: iGan Partners' lead in this round reflects growing investor appetite for diagnostics that slot into existing reimbursement infrastructure rather than waiting on new regulatory approvals — a pragmatic playbook that can shorten the path to commercial scale. For Adenocyte, still at the early growth stage, the real proof point is its USCAP data: four cases of neoplasia caught where MRI and other modalities saw nothing, offering a concrete clinical edge in a cancer where late detection is the primary driver of mortality.
Read more: pr.gulfmainmagazine.com
